# China NMPA Drug Inspection - Marketing Authorization Holder: Shenzhen Jiurui Health Technology Development Co., Ltd.; Trustee: Sinopharm Group Guangdong Global Pharmaceutical Co., Ltd. - Atorvastatin calcium dispersible tablets

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/marketing-authorization-holder-shenzhen-jiurui-health-technology-development-co-ltd-trustee-sinopharm-group-guangdong-global-pharmaceutical-co-ltd/2c2d7fda-a666-43fd-a78b-cbb186d470cc/
Source feed: China

> China NMPA drug inspection for Marketing Authorization Holder: Shenzhen Jiurui Health Technology Development Co., Ltd.; Trustee: Sinopharm Group Guangdong Global Pharmaceutical Co., Ltd. published July 28, 2022. Drug: Atorvastatin calcium dispersible tablets. 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Information Bulletin on Drug Quality Sampling Inspection in Qinghai Province (Issue 1, 2022)
- Company Name: Marketing Authorization Holder: Shenzhen Jiurui Health Technology Development Co., Ltd.; Trustee: Sinopharm Group Guangdong Global Pharmaceutical Co., Ltd.
- Publication Date: 2022-07-28
- Drug Name: Atorvastatin calcium dispersible tablets
- Inspection Finding: qualified

Company: https://www.globalkeysolutions.net/companies/marketing-authorization-holder-shenzhen-jiurui-health-technology-development-co-ltd-trustee-sinopharm-group-guangdong-global-pharmaceutical-co-ltd/85a49333-5537-44c7-832c-447541d683d6/